VANCOUVER, British Columbia, May 27, 2021 (GLOBE NEWSWIRE) — Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) is pleased to highlight an independent research study from the University of Szeged in Hungary describing the use of N,N-dimethyltryptamine (“DMT”) in improving outcomes in a rat stroke model. A preprint of the study was published on…


Previous articleMindMed and Liechti Lab in Basel Switzerland Publish First Pharmacogenetic Data on LSD to Help Guide Personalized Dosing
Next articleRenowned Psychedelic Researcher, James Fadiman, PhD, Joins Wesana Health Scientific Advisory Board